The Prognostic Value and Therapeutic Target Role of Stathmin-1 in Urinary Bladder Cancer
Overview
Authors
Affiliations
Background: The oncoprotein-18/stathmin 1 (STMN1), involved in cell progression and migration, is associated with clinical outcome in breast cancer. Here we aim to investigate its clinical significance in urinary bladder cancer and its possibilities as a therapeutic target.
Methods: Immunohistochemical analyses of STMN1 protein expression were performed in three patient cohorts: cohort I (n=115 Ta, n=115 T1, n=112 T2-4 stages), cohort II, based on randomised controlled trials (n=239 T1-T4), and cohort III of primary tumour/matched metastasis (n=90 T1-T4). The effects of STMN1 on cell proliferation and migration were evaluated in the urinary bladder cancer cell line, T24, by inhibiting STMN1-cellular expression using siRNA.
Results: In cohort I, high STMN1 expression correlated to shorter disease-specific survival hazard ratio (HR)=2.04 (95% confidence interval (CI) 1.13-3.68; P=0.02), elevated p53- (P<0.001) and Ki67-protein levels (P<0.001). The survival result was validated in cohort II: HR=1.76 (95% CI 1.04-2.99; P=0.03). In the metastatic bladder cancer material, 70% of the patients were STMN1-positive in both the primary tumour and matched metastases. In vitro, the growth and migration of the T24 cells were significantly reduced (P<0.01, P<0.0001, respectively), when transfecting the cells with STMN1-siRNA.
Conclusions: STMN1 protein expression has prognostic significance but is primarily a potential treatment target in urinary bladder cancer.
Stathmin 1 expression in neuroendocrine and proliferating prostate cancer.
Shi Y, Yeh Y, Cheng S, Gu X, Yang S, Li L Discov Oncol. 2025; 16(1):19.
PMID: 39776361 PMC: 11711591. DOI: 10.1007/s12672-025-01754-6.
Stathmin 1 Expression in Neuroendocrine and Proliferating Prostate Cancer.
Shi Y, Yeh Y, Cheng S, Gu X, Yang S, Li L Res Sq. 2024; .
PMID: 39711570 PMC: 11661371. DOI: 10.21203/rs.3.rs-5279702/v1.
Kayama E, Uemura M, Onagi A, Meguro S, Ogawa S, Yaginuma K Cancer Med. 2024; 13(22):e70349.
PMID: 39540204 PMC: 11561421. DOI: 10.1002/cam4.70349.
Potential Markers to Differentiate Uterine Leiomyosarcomas from Leiomyomas.
Guo J, Zheng J, Tong J Int J Med Sci. 2024; 21(7):1227-1240.
PMID: 38818470 PMC: 11134592. DOI: 10.7150/ijms.93464.
Kerzeli I, Kostakis A, Turker P, Malmstrom P, Hemdan T, Mezheyeuski A BMC Cancer. 2023; 23(1):605.
PMID: 37391708 PMC: 10311740. DOI: 10.1186/s12885-023-11100-0.